Baseline characteristics for primary and exploratory cohorts (N = 10)
| . | MF-CP (n = 9) . | MF-BP (n = 1) . |
|---|---|---|
| Median age, y (range) | ||
| At diagnosis | 70 (43-77) | 70 |
| At enrollment | 72.5 (45-81) | 74 |
| Female | 5 (56) | 0 |
| Median no. of previous lines of therapy (range) | 3 (1-6) | 4 |
| Previous treatments with ruxolitinib | 8 (89) | 1 |
| Disease subtype | ||
| PMF | 7 (78) | 0 |
| PET-MF | 2 (22) | 0 |
| MF-BP | 0 (0) | 1 |
| DIPSS Plus score | ||
| Intermediate-1 | 2 (22) | 0 |
| Intermediate-2 | 3 (33) | 0 |
| High | 4 (44) | 1 |
| Genetics | ||
| JAK2V617F | 5 (56) | 0 |
| Myeloid molecular panel | ||
| MPL | 2 (22) | 0 |
| CALR | 2 (22) | 0 |
| Triple-negative | 0 (0) | 1 |
| Cytogenetics | ||
| Favorable karyotype | 5 (56) | 0 |
| Unfavorable karyotype | 3 (33) | 0 |
| Unknown | 1 | 1 |
| RBC transfusion dependent | 3 (33) | 1 |
| White blood cell, ×103/µL | 10.40 (3.60-19.94) | 13.30 |
| Hemoglobin, g/dL | 9.5 (6.7-12.1) | 7.90 |
| Platelets, ×103/µL | 63 (31-901) | 42 |
| Median blast, % (range) | 2 (0-7) | 20 |
| Palpable spleen | 7 (78) | 0* |
| Median palpable spleen length, cm (range) | 12 (5-20) | NA |
| . | MF-CP (n = 9) . | MF-BP (n = 1) . |
|---|---|---|
| Median age, y (range) | ||
| At diagnosis | 70 (43-77) | 70 |
| At enrollment | 72.5 (45-81) | 74 |
| Female | 5 (56) | 0 |
| Median no. of previous lines of therapy (range) | 3 (1-6) | 4 |
| Previous treatments with ruxolitinib | 8 (89) | 1 |
| Disease subtype | ||
| PMF | 7 (78) | 0 |
| PET-MF | 2 (22) | 0 |
| MF-BP | 0 (0) | 1 |
| DIPSS Plus score | ||
| Intermediate-1 | 2 (22) | 0 |
| Intermediate-2 | 3 (33) | 0 |
| High | 4 (44) | 1 |
| Genetics | ||
| JAK2V617F | 5 (56) | 0 |
| Myeloid molecular panel | ||
| MPL | 2 (22) | 0 |
| CALR | 2 (22) | 0 |
| Triple-negative | 0 (0) | 1 |
| Cytogenetics | ||
| Favorable karyotype | 5 (56) | 0 |
| Unfavorable karyotype | 3 (33) | 0 |
| Unknown | 1 | 1 |
| RBC transfusion dependent | 3 (33) | 1 |
| White blood cell, ×103/µL | 10.40 (3.60-19.94) | 13.30 |
| Hemoglobin, g/dL | 9.5 (6.7-12.1) | 7.90 |
| Platelets, ×103/µL | 63 (31-901) | 42 |
| Median blast, % (range) | 2 (0-7) | 20 |
| Palpable spleen | 7 (78) | 0* |
| Median palpable spleen length, cm (range) | 12 (5-20) | NA |
Data are n (%), unless otherwise noted.
CALR, calreticulin; JAK2, Janus protein kinase 2; MPL, myeloproliferative leukemia; NA; not applicable; PET-MF, post-essential thrombocythemia myelofibrosis; PMF, primary myelofibrosis; RBC, red blood cell.
MF-BP patient had a splenectomy.